GlassScriptPhysician profile
Adil M Mohiuddin
NPI 1073065983
$2,306.02
in general payments reported to CMS, 2019-2025
30 companies · $415 in 2025
The $415 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $363 · 2021: $333 · 2022: $369 · 2023: $303 · 2024: $369 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.79 | 2021-2025 | |
| Lilly USA, LLC | $314.55 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $307.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $133.62 | 2019-2023 | |
| Glaxosmithkline, LLC. | $123.34 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $112.09 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.46 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $84.58 | 2020-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $76.39 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.51 | 2021-2022 | |
| Astellas Pharma US INC | $52.47 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.87 | 2025 | Caplyta |
| Rigel Pharmaceuticals, INC. | $49.98 | 2024 | Tavalisse, Rezlidhia |
| Sanofi-Aventis U.S. LLC | $47.53 | 2020 | |
| Janssen Pharmaceuticals, INC | $47.23 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.78 | 2023-2024 | Repatha, Otezla |
| Melinta Therapeutics, LLC | $41.12 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.96 | 2022-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $27.59 | 2023 | |
| Axsome Therapeutics, INC. | $27.55 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $26.00 | 2024 | Fanapt |
| Paratek Pharmaceuticals, INC. | $22.74 | 2020 | |
| Blueprint Medicines Corporation | $19.80 | 2024 | Ayvakit |
| Lundbeck LLC | $18.52 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $15.65 | 2019 | |
| Exact Sciences Corporation | $13.84 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $12.88 | 2022 | |
| Sumitomo Pharma America, INC. | $12.60 | 2023 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $11.91 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.67 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.